Standard immunotherapy is the most recent advent in treatment of Oral Squamous Cell Carcinoma (OSCC) and cancer in general. More understanding of tumor inflammation and how it can vary from one patient to the other is critical for successful use of the technology to benefit OSCC patients. Therefore, research work describing different inflammatory phenotypes of OSCC is encouraged for better patient stratification, and accordingly better targeted treatment strategies with the ultimate goal of enhanced personalized immunotherapy and immunoprevention.
Current OSCC therapeutic modalities include non specific chemotherapy and radiotherapy approaches with limited targeted therapy options like Cetuximab as EGFR inhibitor. More understanding of tumor inflammation will enhance OSCC patient stratification and accordingly personalized targeted therapy.
This Research Topic promotes research that emphasizes current biomarkers or revealing novel ones, whether single or complex signatures, of oncologic or immune platform, or combined immuno-oncologic signatures. This area of research focus will help stratify OSCC patients and accordingly open avenues to new personalized lines of treatment of OSCC.
Standard immunotherapy is the most recent advent in treatment of Oral Squamous Cell Carcinoma (OSCC) and cancer in general. More understanding of tumor inflammation and how it can vary from one patient to the other is critical for successful use of the technology to benefit OSCC patients. Therefore, research work describing different inflammatory phenotypes of OSCC is encouraged for better patient stratification, and accordingly better targeted treatment strategies with the ultimate goal of enhanced personalized immunotherapy and immunoprevention.
Current OSCC therapeutic modalities include non specific chemotherapy and radiotherapy approaches with limited targeted therapy options like Cetuximab as EGFR inhibitor. More understanding of tumor inflammation will enhance OSCC patient stratification and accordingly personalized targeted therapy.
This Research Topic promotes research that emphasizes current biomarkers or revealing novel ones, whether single or complex signatures, of oncologic or immune platform, or combined immuno-oncologic signatures. This area of research focus will help stratify OSCC patients and accordingly open avenues to new personalized lines of treatment of OSCC.